Dr. Reddy’s Laboratories (NYSE: RDY), a prominent Indian pharmaceutical company, has launched its biosimilar Versavo (bevacizumab) in the UK market, presenting a challenge to Roche’s established cancer therapy Avastin. Versavo, a biosimilar to Avastin, has been approved for the treatment of various metastatic cancers, including colorectal cancer, non-squamous non-small cell lung cancer (NSCLC), glioblastoma, renal cell carcinoma (RCC), cervical cancer, ovarian cancer, and breast cancer.
This marks the first biosimilar from Dr. Reddy’s to be introduced in the UK, expanding the company’s footprint in the global biosimilars market. Versavo has already received market approval in Jamaica, Nepal, Thailand, Ukraine, and is sold under the brand name Persivia in Colombia.
According to the public report, Avastin faces competition in the UK from several biosimilars, including products from Amgen (NASDAQ: AMGN), Celltrion (KRX: 068270), Fresenius Kabi’s (FRA: FREA) mAbxience, Pfizer (NYSE: PFE), Stada, and Viatris (NASDAQ: VTRS), indicating a robust competitive landscape for cancer treatments in the country.- Flcube.com
